Nuo Therapeutics Files 8-K: Material Agreement & Equity Sales

TL;DR

Nuo Therapeutics signed a big deal and sold some stock, filing an 8-K on 9/18/24.

AI Summary

Nuo Therapeutics, Inc. entered into a material definitive agreement on September 18, 2024. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. Specific details of the agreement and sales were not provided in this summary.

Why It Matters

This filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial standing and future operations.

Risk Assessment

Risk Level: medium — The filing mentions a material definitive agreement and unregistered sales of equity, which can introduce financial and operational risks depending on the specifics not detailed here.

Key Players & Entities

• Nuo Therapeutics, Inc. (company) — Registrant
• September 18, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.0001 — f the Company's common stock, par value $0.0001 per share (the "Common Stock") at a pri
• $0.75 — hare (the "Common Stock") at a price of $0.75 per share for gross proceeds of $849,12
• $849,125 — f $0.75 per share for gross proceeds of $849,125 (the "Private Placement"). The closing
• $93,750 — der of the Company. Mr. Sheedy invested $93,750 in the Private Placement. The proceeds

Filing Documents

• aurx20240913c_8k.htm (8-K) — 24KB
• ex_724032.htm (EX-10.1) — 129KB
• 0001437749-24-029602.txt ( ) — 302KB
• aurx-20240918.xsd (EX-101.SCH) — 3KB
• aurx-20240918_def.xml (EX-101.DEF) — 10KB
• aurx-20240918_lab.xml (EX-101.LAB) — 14KB
• aurx-20240918_pre.xml (EX-101.PRE) — 11KB
• aurx20240913c_8k_htm.xml (XML) — 3KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On September 18, 2024, Nuo Therapeutics, Inc. (the "Company") entered into a Securities Purchase Agreement, dated as of September 13, 2024, with certain accredited investors for the sale of 1,132,167 shares of the Company's common stock, par value $0.0001 per share (the "Common Stock") at a price of $0.75 per share for gross proceeds of $849,125 (the "Private Placement"). The closing of the Private Placement occurred on September 19, 2024. The investors in the Private Placement included Charles E. Sheedy, a principal stockholder of the Company. Mr. Sheedy invested $93,750 in the Private Placement. The proceeds of the Private Placement will be used for working capital purposes. As a result of the Private Placement, the number of shares of Common Stock outstanding is 46,598,405. The description of the Securities Purchase Agreement is qualified in its entirety by reference to the full text of such agreement filed as Exhibits 10.1 hereto.

02 Unregistered Sales of Equity Securities

Item 3.02 Unregistered Sales of Equity Securities. The disclosure required by this Item as included in Item 1.01 of this report is incorporated herein by reference. The shares of Common Stock were offered and sold pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 thereunder, in a transaction not involving any public offering.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 10.1 Securities Purchase Agreement 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Nuo Therapeutics, Inc. By: /s/ David E. Jorden David E. Jorden Chief Executive and Chief Financial Officer Date: September 19, 2024

View Full Filing

View this 8-K filing on SEC EDGAR